S. Schauer

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Stephen P Schauer, S. Schauer, Stephen P. Schauer, S Schauer, Stephen Schauer
Publication record
18 papers · 1,166 citations · H-index 10

PAPERS

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
202358 citationsauthor #10
Concordance between [18F] GTP1 PET and fluid tau biomarkers in the Tauriel phase II Study
20210 citationsauthor #5
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease
202186 citationsauthor #35
Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy.
2019371 citationsauthor #6
Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays
201811 citationsauthor #1
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
2018126 citationsauthor #13
P1‐284: BASELINE RECOVERY AND LONGITUDINAL STABILITY OF CEREBROSPINAL FLUID AMYLOID‐β PEPTIDES: AN EVALUATION OF COLLECTION METHODS, LONGITUDINAL ASSAY PERFORMANCE, AND BIOMARKER STABILITY OVER A 2‐YEAR PERIOD
20180 citationsauthor #1
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
20141 citationsauthor #2
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
2014125 citationsauthor #2
P1–168: Multiplexed MRM assay verifies candidate Alzheimer's disease biomarkers in CSF
20130 citationsauthor #2
Abstract C234: Regulated immunomodulators expression using the RheoSwitch Therapeutic System® platform in human mesenchymal stem cells.
20130 citationsauthor #10
P1–177: Effects of aliquot size, Tween‐20 and tube type on beta‐amyloid 42, tau and p‐tau(181) measurements
20130 citationsauthor #1
Mechanistic Pharmacokinetic-Pharmacodynamic Modeling of BACE1 Inhibition in Monkeys: Development of a Predictive Model for Amyloid Precursor Protein Processing
201320 citationsauthor #11
Abstract B127: Pharmacodynamics and functionality of RheoSwitch® regulated immunomodulatory proteins, expressed from a multigenic embedded cellular bioreactor following intramuscular electroporation in mice.
20130 citationsauthor #2
Skeletal muscle damage and impaired regeneration due to LPL-mediated lipotoxicity
201272 citationsauthor #5
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E
2010237 citationsauthor #12
Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295.
201056 citationsauthor #29
Differential response of tumor cell lines to inhibition of the mitotic checkpoint regulator and mitotic kinesin, CENP-E
20074 citationsauthor #3

TIMELINE

2007 4 citations

2010 293 citations

2012 72 citations

2013 20 citations

2014 126 citations

2018 137 citations

2019 371 citations

2021 86 citations

2023 58 citations

S. Schauer

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT